PRESENCE-ALZ (Mevidalen)

The Lilly PRESENCE-ALZ study is looking for volunteers who have mild to moderate memory loss and may be interested in clinical research. This study is a Phase II therapeutic study to determine the effectiveness and safety of Mevidalen (an oral tablet) in patients with Alzheimer’s disease. Participation in this clinical research trial will not only offer the opportunity to assist in providing investigational treatment to those suffering, but may offer potential benefits to participants.

 

Who is eligible?

  • People between the ages of 50 and 80 diagnosed with mild Alzheimer's or moderate Alzheimer's
  • Those with gradual and progressive decline in memory function for 6 or more months
  • Have a reliable family member, friend, or care partner who knows you well, connects with you daily, and can accompany you to all visits at the research site

 

What is involved?

The PRESENCE-ALZ study is a 6-month study that includes cognitive testing, collection of demographic information, medical history, physical assessment, monitoring of vital signs, regular ECGs, blood draws, and administering investigational product. Our site staff will provide ongoing review of the results and discuss with the volunteer any findings. Those eligible in screening will continue into the study for 6 months of participation with an active study partner.

 

For more information, please contact:

Study Coordinator:  Madina Akhmedova, 206-685-8630 or Madina03@uw.edu 

Study flyer